Prevalence and impact of chronic dysglycaemia among patients with COVID-19 in Swedish intensive care units: a multicentre, retrospective cohort study

• Published in: BMJ open 2023-09, Vol.13 (9), p.e071330
• Main Authors: Balintescu, Anca, Rysz, Susanne, Hertz, Carl, Grip, Jonathan, Cronhjort, Maria, Oldner, Anders, Svensen, Christer, Mårtensson, Johan
• Format: Article
• Language: English
• Subjects: Adult intensive & critical care; Body mass index; Clinical outcomes; Cohort analysis; Comorbidity; COVID-19; COVID-19 - epidemiology; COVID-19 - therapy; Diabetes; DIABETES & ENDOCRINOLOGY; General diabetes; Glycated Hemoglobin; Hemoglobin; Humans; Hypertension; Intensive Care; Intensive Care Units; Laboratories; Length of stay; Medical prognosis; Medical records; Medicin och hälsovetenskap; Mortality; Observational studies; Patients; Population; Prediabetic State; Prevalence; Regression analysis; Retrospective Studies; Severe acute respiratory syndrome coronavirus 2; Sweden - epidemiology
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-071330

ObjectiveUsing glycated haemoglobin A1c (HbA1c) screening, we aimed to determine the prevalence of chronic dysglycaemia among patients with COVID-19 admitted to the intensive care unit (ICU). Additionally, we aimed to explore the association between chronic dysglycaemia and clinical outcomes related to ICU stay.DesignMulticentre retrospective observational study.SettingICUs in three hospitals in Stockholm, Sweden.ParticipantsCOVID-19 patients admitted to the ICU between 5 March 2020 and 13 August 2020 with available HbA1c at admission. Chronic dysglycaemia was determined based on previous diabetes history and HbA1c.Primary and secondary outcomesPrimary outcome was the actual prevalence of chronic dysglycaemia (pre-diabetes, unknown diabetes or known diabetes) among COVID-19 patients. Secondary outcome was the association of chronic dysglycaemia with 90-day mortality, ICU length of stay, duration of invasive mechanical ventilation (IMV) and renal replacement therapy (RRT), accounting for treatment selection bias.ResultsA total of 308 patients with available admission HbA1c were included. Chronic dysglycaemia prevalence assessment was restricted to 206 patients admitted ICUs in which HbA1c was measured on all admitted patients. Chronic dysglycaemia was present in 82.0% (95% CI 76.1% to 87.0%) of patients, with pre-diabetes present in 40.2% (95% CI 33.5% to 47.3%), unknown diabetes in 20.9% (95% CI 15.5% to 27.1%), well-controlled diabetes in 7.8% (95% CI 4.5% to 12.3%) and uncontrolled diabetes in 13.1% (95% CI 8.8% to 18.5%). All patients with available HbA1c were included for the analysis of the relationship between chronic dysglycaemia and secondary outcomes. We found no independent association between chronic dysglycaemia and 90-day mortality, ICU length of stay or duration of IMV. After excluding patients with specific treatment limitations, no association between chronic dysglycaemia and RRT use was observed.ConclusionsIn our cohort of critically ill COVID-19 patients, the prevalence of chronic dysglycaemia was 82%. We found no robust associations between chronic dysglycaemia and clinical outcomes when accounting for treatment limitations.